« Back
Home /
Laquinimod

Laquinimod

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	10mM/1mL
Item no.	HY-13010-10mM
Targets	NF-κB; Apoptosis
CASRN	248281-84-7
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	356.80
Clinical_Information	Launched
Manufacturers Research_Area	Inflammation/Immunology
Solubility	DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturers Target	Apoptosis; NF-κB
Isoform	NF-κB
Pathway	Apoptosis; NF-κB
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13010-10mM-safety-datasheet.pdf